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ABSTRACT Transcription factor IIH (TFIIH) is a mul-
tisubunit protein complex essential for both the initiation of
RNA polymerase class II (pol II)-catalyzed transcription and
nucleotide excision repair of DNA. Recent studies have shown
that TFIIH copurifies with the cyclin-dependent kinase (cdk)-
activating kinase complex (CAK) that includes cdk7, cyclin H,
and p36/MAT1. Here we report the isolation of two TFIIH-
related complexes: TFIIH* and ERCC2/CAK. TFIIH* con-
sists of a subset of the TFIIH complex proteins including
ERCC3 (XPB), p62, p44, p41, and p34 but is devoid of
detectable levels of ERCC2 (XPD) and CAK ERCC2/CAK
was isolated as a complex that exhibits CAK activity that
cosediments with the three CAK components (cdk7, cyclin H,
and p36/MAT1) as well as the ERCC2 (XPD) protein. TFIIH*
can support pol II-catalyzed transcription in vitro with lower
efficiency compared with TFIIH. This TFIIH*-dependent
transcription reaction was stimulated by ERCC2/CAK. The
ERCC2/CAK and TFIIH* complexes are each active in DNA
repair as shown by their ability to complement extracts
prepared from ERCC2 (XPD)- and ERCC3 (XPB)-deficient
cells, respectively, in supporting the excision ofDNA contain-
ing a cholesterol lesion. These data suggest that TFIIH* and
ERCC2/CAK interact to form the TFIIH holoenzyme capable
of efficiently assembling the pol II transcription initiation
complex and directly participating in excision repair reac-
tions.
Transcription factor IIH (TFIIH) is a multisubunit protein
complex required both for RNA polymerase class II (pol
II)-catalyzed transcription and for DNA nucleotide excision
repair (excision repair) (1). There are at least eight polypep-
tides with molecular masses of 89, 80, 62, 44, 41, 40, 37, and 34
kDa that copurify with mammalian TFIIH. Most of these
subunits have been cloned. p89 and p80 are the gene products
of ERCC3 (XPB) and ERCC2 (XPD) (2, 3). Mutations in
either of these genes result in excision repair deficiencies that
are linked to the genetic disease xeroderma pigmentosum (XP)
groups B and D, respectively (1, 4). p62 and p44 are mamma-
lian counterparts of the yeast TFB1 and SSL1 gene products
that have been shown to be involved in DNA repair (5). p44
and p34 exhibit partial sequence homology and contain zinc-
finger motifs that may be important for anchoring TFIIH to
DNA during the initiation of transcription (6).
It has been shown that the p40 and p37 subunits of TFIIH
are identical to the cyclin-dependent kinase (cdk)-activating
kinase (CAK) components cdk7 and cyclin H, and that CAK
is responsible for TFIIH-associated carboxyl-terminal domain
(CTD) kinase activity (7-10). The CAK activity was initially
identified by Solomon et al. (11) in extracts of Xenopus as a
protein kinase activity specifically required for the activation
of a cdk/cyclin complex. It was subsequently found that CAK
phosphorylates a conserved threonine residue within the T
loop of a CDK (Thr-160 in CDK2 or Thr-161 in CDC2) (12).
Recently, several groups (13-15) have identified a third com-
ponent of CAK called p36/MAT1, which promotes the as-
sembly of cdk7 and cyclin H, and is also tightly associated with
TFIIH.
TFIIH is a general transcription factor required for the
initiation of pol II-catalyzed transcription. As summarized by
Zawel and Reinberg (16), formation of the pol II initiation
complex with basal transcription factors is initiated by the
binding of the TATA-binding protein and its associated factors
to a core TATA-containing promoter element. This DNA-
protein complex then recruits TFIIB and subsequently TFIIF,
through which pol II is loaded. The pol II preinitiation complex
is further modified by the binding of TFIIE and TFIIH before
the initiation of RNA synthesis. In the absence of TFIIH, pol
II stalls immediately downstream of the transcription start site
(17), suggesting that TFIIH relieves a block that prevents pol
II from initiating RNA synthesis.
TFIIH function in excision repair requires its ATPase/
helicase activities intrinsic to both the ERCC2 (XPD) and
ERCC3 (XPB) subunits (1, 4). As proposed by Sancar (18),
following the initial recognition and binding of XP-A to the
damaged site, the duplex region around the lesion is probably
unwound to allow the structure-specific (Y-type) DNA endo-
nucleases ERCC1/XP-F and XP-G to make incisions at the 5'
and 3' sides of the lesion, respectively. In the presence of the
eukaryotic single-stranded DNA binding protein (HSSB or
RP-A), TFIIH is an excellent candidate for participation in this
unwinding reaction.
The elucidation of the function of TFIIH in both transcrip-
tion and excision repair, as well as the significance of the
relationship between TFIIH and CAK, requires analysis of
interactions among the TFIIH subunits and their assemblage
into the TFIIH holoenzyme. In this report, we describe the
isolation and characterization of two TFIIH-related com-
plexes, TFIIH* and ERCC2/CAK, and their ability to support
transcription and excision repair.
MATERIALS AND METHODS
CFEs. Chinese hamster ovary cell lines wild-type (AA8,
CRL1859), CG2/XPD (UV5, CRL1865), CG3/XPB (UV24,
CRL1866), and CG5/XPG (UV135, CRL1867)) were from the
American Type Culture Collection. Cell-free extracts (CFE) were
Abbreviations: NP40, Nonidet P-40; TFIIH, transcription factor IIH;
cdk, cyclin-dependent kinase; CAK, cdk-activating kinase; pol II, RNA
polymerase class II; XP, xeroderma pigmentosum; CTD, carboxyl-
terminal domain; CFE, cell-free extract.
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prepared by the method of Manley et al. (19) and stored as
described (20).
Purification of Human ERCC2/CAK Complex. ERCC2/
CAK was isolated from a 0.7 M NaCl phosphocellulose
fraction that was prepared from cytosolic extracts of HeLa
cells (886 ml at 9.6 mg of protein per ml) as described (21). The
complex was purified based on its ability to catalyze the
phosphorylation of histone Hi by the combined action of
GST-CDK2 and cyclin A (both were expressed and purified
from bacteria; ref. 22). One unit of CAK activity catalyzed the
incorporation of 1 nmol of [32p] into histone Hi in 30 min. The
0.7 M phosphocellulose fraction (122 ml at 3.1 mg of protein
per ml) was diluted 20-fold with bufferA [25 mM Tris HCl, pH
7.5/10% (vol/vol) glycerol/i mM EDTA/1 mM DTT/0.01%
Nonidet P-40 (NP-40)/0.1 mM phenylmethylsulfonyl fluoride
(PMSF)/0.2 mg/liter antipain/0.1 mg/liter leupeptin] and
chromatographed on a DEAE-Sepharose CL6B column (2.5
x 20 cm, 100 ml) equilibrated with 1 liter of buffer A
containing 0.025 M NaCl followed by washing with 300 ml of
buffer A plus 0.025 M NaCl. CAK activity eluting from the
DEAE column with 300 ml of buffer A plus 0.15 M NaCl was
passed directly onto an S-sepharose column (2.5 x 6.5 cm, 32
ml) pre-equilibrated with buffer A plus 0.15 M NaCl. CAK
activity, which flowed through the S-sepharose column, was
passed directly onto a heparin-sepharose column (1.0 x 2.5
cm, 2 ml) pre-equilibrated with the same buffer and bound
proteins were eluted with a 40 ml gradient of 0.15 to 1.0 M
NaCl in buffer A. The CAK activity eluted at 0.37 M NaCl
(2550 units; 12 ml at 0.06 mg of protein per ml) and was diluted
2.5-fold with buffer A before chromatography on a Cibacron
blue 3GA-agarose column (Sigma, 0.7 x 2.2 cm, 0.85 ml)
equilibrated with 10 ml of buffer A plus 0.15 M NaCl. The
column was washed successively with 5 ml of the same buffer
containing 0.15 M and 0.5 M NaCl. The CAK activity was
eluted with buffer A containing 1.0 M NaCl (3 ml) and 2.0 M
NaCl plus 40% ethylene glycol (6 ml). The two eluates were
pooled and dialyzed against 2 liters of bufferA plus 0.1 M NaCl
for 4 h at 0°C. This material (3225 units; 10 ml at 0.04 mg of
protein per ml) was concentrated using a Centriflow-25 cone
(Amicon) and then subjected to glycerol gradient centrifuga-
tion [5 ml, 15-35% (vol/vol) in buffer A plus 0.15 M NaCl,
centrifuged at 1.9 x 105 x g for 23 h at 4°C]. CAK complexes
sedimented at 4.4 S or 7.4 S were separately pooled and further
concentrated by a Centriflow-25 cone (4.4S complex, 985
units; 7.4S complex, 264 units).
Isolation of Human TFIIH*. TFIIH* was isolated based on
the copurification of two of the TFIIH subunits, ERCC3
(XPB) and p62, that were followed during chromatography by
immunoblot analyses. The 0.7 M phosphocellulose fraction
(115 ml at 0.96 mg of protein per ml), derived from cytosolic
extracts of HeLa cells was diluted 15-fold with buffer A and
chromatographed on a DEAE-Sepharose CL6B column (2.5
x 7.3 cm, 36 ml) equilibrated with 400 ml of buffer A
containing 0.025 M NaCl. After washing with 100 ml of buffer
A plus 0.025 M NaCl, TFIIH* was eluted from the DEAE
column with 100 ml of buffer A plus 0.15 M NaCl and was
passed directly onto an S-sepharose column (1.5 x 4.7 cm, 8.3
ml) pre-equilibrated with buffer A plus 0.15 M NaCl. Proteins
bound to the S-sepharose column were eluted with a 100 ml
gradient of 0.15 to 1.0 M NaCl in buffer A. TFIIH* eluted at
0.28 M NaCl (15 ml at 0.4 mg of protein per ml) and was
directly chromatographed on a Hydroxylapatite column (1.5 x
0.9 cm, 1.6 ml) equilibrated with 20 ml of buffer B [20 mM
potassium phosphate, pH 7.0/0.3 M NaCl/10% (vol/vol)
glycerol/i mM EDTA/1 mM DTT/0.01% NP-40/0.1 mM
PMSF/0.2 mg/liter antipain/0.1 mg/liter leupeptin]. The col-
umn was eluted with a 20 ml linear gradient of 0.02 to 0.8 M
potassium phosphate (pH 7.0) in buffer B. TFIIH* eluted at
0.3 M potassium phosphate (4.3 ml at 0.79 mg of protein per
ml). This fraction was then diluted 5-fold with buffer A
containing 0.15 M NaCl and subsequently concentrated 10-
fold using a Centriflow-25 cone. The resulting material was
subjected to two rounds of glycerol gradient centrifugation
[15-35% (vol/vol) in buffer A plus 0.2 M NaCl, centrifuged at
1.9 x 105 x g for 20 h at 4°C]. Approximately 50 ,ug of TFIIH*
was obtained.
Preparation of RNA pol II Transcription Factors and in
Vitro Transcription Assay. Transcription factors were purified
as described (23) with the exception of TFIIA. A Ni2+-NTA
agarose column was used for the purification ofTFIIA because
there is an intrinsic poly-histidine sequence (amino acids
81-87) present in the a subunit of TFIIA (24). In vitro
transcription reactions were carried out as described (23).
Excision Repair Substrate and Excision Assay. The DNA
substrate used in the excision assay was a double-stranded 140
mer containing a cholesterol "lesion" in lieu of a normal base
at position 70 of one strand that was prepared as described
(25). Excision assay was carried out with CFE (50 ,ug at 2
mg/ml) and substrate DNA (2-3 fmol) in 25 ,ul and incubated
at 30°C for 60 min. For CFE complementation, 25 ,ug of each
CFE was used or 1-2 ,ul of purified protein was added to 50 ,ug
of CFE. Following incubation, the DNA was recovered and
analyzed as described (20).
RESULTS
Isolation and Identification of an ERCC2/CAK Complex.
Extensive purification of CAK complexes from HeLa cell
extracts was carried out to gain a better understanding of the
relationship between CAK and TFIIH. CAK activity was
measured by its ability to activate histone Hi phosphorylation
by the CDK2/cyclin A complex. The requirements for this
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FIG. 1. Separation of two peaks of CAK activity during glycerol
gradient centrifugation. An aliquot of the CAK heparin-Sepharose
fraction (254 units) was separated on a 15-35% glycerol gradient. (A)
Reactions contained 0.2 ,g of GST-CDK2 (lanes 1, 3, and 5-15), 0.5
,ug of cyclin A (lanes 1, 4-15), 1 ,ul of the heparin-Sepharose fraction
(lanes 2-5), 2 ,lI of each glycerol gradient fraction as indicated (lanes
6-15), and were assayed for CAK activities as previously described
(11) and the autoradiogram is shown. The [32p] incorporation into
histone H1 in the reactions shown in lanes 1-5 was 0.2, 0.5, 0.5, 0.6, and
94 pmol, respectively. (B) The quantitation of reactions shown in lanes
6-15. In a parallel gradient, protein standards sedimented as follows:
catalase (11.2S), fraction 4; aldolase (7.4S), fraction 12; and BSA
(4.4S), fraction 18, respectively.
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either GST-CDK2 and cyclin A or CAK alone, no Hi kinase
activity was detected (lanes 1 and 2). Following the addition of
CAK, efficient histone Hi phosphorylation was observed (lane
5). This activation required both CDK2 and cyclin A (lanes 3
and 4).
To determine whether the CAK and TFIIH subunits asso-
ciate, the CAK fraction was subjected to a 15-35% glycerol
gradient centrifugation. Gradient fractions were assayed for
CAK activity (Fig. 1A, lanes 6-15). Two distinct peaks ofCAK
activity were observed (Fig. 1B): a minor peak at 7.4S and a
major peak around 4.4S.
To identify the components present in the two peaks, the
4.4S and 7.4S CAK complexes were separately pooled, con-
centrated, and further purified by a second glycerol gradient.
Analyses of the glycerol gradient fractions derived from the
7.4S CAK complex revealed the presence of CAK activity that
peaked at fractions 12 and 14, at 7.4S (Fig. 2A). The shoulder
of activity detected in fraction 18 and 20 most likely resulted
from the presence of the 4.4S CAK complex.
The fractions were subjected to immunoblot analyses to
detect the presence of CAK components (cdk7, cyclin H, and
p36) as well as the TFIIH subunits of ERCC2 (XPD), ERCC3
(XPB) and p62. As shown in Fig. 2B, all three CAK compo-
nents and ERCC2 (XPD) protein peaked in fractions 12 and
14, coincidental with CAK activity. Neither ERCC3 (XPB) nor
p62 were detected in these fractions (data not shown, but see
Fig. 3C).
To determine whether ERCC2 (XPD) could form an im-
munoprecipitable complex with the CAK components, a CAK
fraction enriched with CAK activity and ERCC2 (XPD)
protein was immunoprecipitated with acdk7 antibody and the
precipitates were probed for the presence of cdk7, cyclin H,
p36, and ERCC2 (XPD) proteins by immunoblot analyses. As
shown in Fig. 2C, acdk7 (lane 3) but not the control serum
(lane 2), immunoprecipitated all of the CAK components as
well as ERCC2 (XPD). This finding suggests that ERCC2
(XPD) and CAK interact to form a complex.
Glycerol gradient analysis of the 4.4S CAK complex re-
vealed a single peak ofCAK activity at 4.4S that included cdk7,
cyclin H, and p36 (data not shown). None of the TFIIH
subunits ERCC2 (XPD), ERCC3 (XPB), and p62 were asso-
ciated with this CAK activity (data not shown, but see Fig. 3C).
TFIIH* Is a Subset of TFIIH Lacking Detectable Levels of
ERCC2 (XPD) and CAK. A TFIIH-related complex, desig-
nated TFIIH*, was isolated from HeLa cell extracts based on
the copurification of the TFIIH subunits ERCC3 (XPB) and
p62. The TFIIH* complex was analyzed by centrifugation
through a 15-35% glycerol gradient. Immunoblot analysis of
these fractions (shown in Fig. 3A) indicated that ERCC3
(XPB) and p62 proteins cosedimented and peaked in fractions
12, 14, and 16, around 9.6S. Denaturing polyacrylamide gel/
silver staining analysis of the TFIIH* fractions revealed that
ERCC3 (XPB) and p62 comigrated with three additional
polypeptides, p44, p4l, and p34 (Fig. 3B), which were previ-
ously reported to be components of the mammalian TFIIH
holoenzyme (1). Like TFIIH, TFIIH* contained DNA-
dependent ATPase activity (data not shown).
Additional immunoblot analyses were carried out to deter-
mine whether TFIIH* associated with ERCC2 (XPD) and
CAK components. For comparison, a preparation enriched
with the TFIIH holoenzyme isolated from HeLa cells (a gift
of R. Drapkin and D. Reinberg, University of Medicine and
Dentistry of New Jersey, Piscataway), as well as the CAK and
ERCC2/CAK complexes, were analyzed in parallel. As shown
in Fig. 3C, TFIIH contained p62, ERCC3 (XPB), ERCC2
(XPD), cdk7, cyclin H, and p36 (lane 4). In contrast, TFIIH*
contained high levels of ERCC3 (XPB) and p62, but lacked
detectable amounts of ERCC2 (XPD) or CAK (lane 1). A very
faint band detected with aERCC2 antibody (lane 1) was not
likely to be ERCC2 (XPD) because it was reproducibly
observed to migrate slightly slower than ERCC2 (XPD). As
shown in lanes 2 and 3, the 4.4S or 7.4S CAK complexes both
contain the CAK components but were devoid of the ERCC3
(XPB) and p62 proteins. Although the 7.4S CAK complex also
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FIG. 2. (A and B) Cosedimentation of CAK activity with the ERCC2 (XPD) protein. An aliquot of the glycerol gradient-isolated 7.4S peak
fractions (94 units) was concentrated and centrifuged through a second 15-35% glycerol gradient. (A) The distribution of CAK activity in the
glycerol gradient fractions (3 fil) was determined. The sedimentations of protein standards catalase (11.2S), aldolase (7.4S), and BSA (4.4S) are
shown. (B) Immunoblot assays of the glycerol gradient fractions (20 ,ul). The immunoreactive polypeptides were visualized by the Enhanced
Chemiluminescence (Amersham). Nitrocellulose membranes were sequentially probed, stripped, and reprobed with different antibodies according
to manufacturer's instructions. (C) CAK components and ERCC2 (XPD) interact to form an immunoprecipitable complex. Aliquots of the CAK
Cibacron blue 3GA fraction (27 units per reaction) were immunoprecipitated with 3 ,ul of either preimmune serum (lane 2) or acdk7 antibody
(lane 3). The immunocomplexes were washed three times, 0.5 ml each, with a solution containing 50 mM Tris HCl (pH 8.0), 0.25 M NaCl, 0.5%
NP-40, and 5 mM EDTA, before immunoblot analyses using antibodies against cdk7, cyclin H, p36, or ERCC2 (XPD). Lane I shows the immunoblot
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FIG. 3. (A) Cosedimentation of ERCC3 (XPB) aI
during glycerol gradient centrifugation. An immunob
glycerol gradient fractions (10 ,ul) of TFIIH* using bot
ap62 antibodies is shown. (B) Denaturing polyacrylan
silver staining analysis of TFIIH* glycerol gradient fr
The molecular mass size markers are indicated on t
positions of the TFIIH subunits are indicated on
Immunoblot analysis of TFIIH, TFIIH*, CAK, and
fractions. Lanes: 1, 15 Al (=150 ng) of TFIIH* gl'
fraction 14 (Fig. 3A); 2, =15 ng of 4.4S CAK fractio
glycerol gradient purification; 3, -10 ng of 7.4S CAK/l
isolated after glycerol gradient centrifugation; 4, 0.l
DEAE-5PW fraction (total pool; a gift of Drs. R. E
Reinberg).
Consistent with these observations, TFIIH* cont
the CAK activity of the TFIIH holoenzyme (dat
Effects of ERCC2/CAK and TFIIH* on pol
Transcription. The influence ofTFIIH, TFIIH*,
CAK on RNA synthesis was examined in reactic
highly purified pol II, TFIIA, TFIIB, TFIID, 1
Gal4 activator, and coactivator PC4 (Fig. 4). In t
TFIIH, RNA synthesis was not observed (lane 1
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FIG. 4. Effect of TFIIH* and ERCC2/CAK on pol II-catalyzed
transcription in vitro. In vitro transcription with purified proteins was
carried out at 30°C for 60 min in a mixture (25 ,ul) containing 50 ng
of Ni-affinity purified TFIIA, 20 ng of recombinant TFIIB, 50 ng of
affinity-purified TFIID, 10 ng of recombinant TFIIE (a+13), 20 ng of
-p89 (ERICC3) TFIIF (RAP30+RAP74), 150 ng of RNA pol II, 30 ng of Gal4-AH,
200 ng of recombinant PC4, and 100 ng of pG5HMC2AT as template
p62 in the presence of 20 mM Hepes-KOH (pH 8.2), 0.5 mg/ml BSA, 70
Jp44 mM KCl, 4 mM MgCl2, 5 mM DTT, 0.5 mM each of ATP and UTP,
p4 125 ,uM CTP, 0.1 mM 3'-O-methyl GTP and 10 ,uCi (1 Ci = 37 GBq)of [a-32P]CTP. Reactions shown in lanes 2-7 were supplemented with
.p34 purified TFIIH fraction as follows: lanes 2 and 5, 20 ng (total protein);
lanes 3 and 6, 40 ng; and lanes 4 and 7, 80 ng. Reactions shown in lanes
11-16 were supplemented with the glycerol gradient purified TFIIH*
fraction as follows: lanes 11 and 14, 15 ng; lanes 12 and 15, 30 ng; and
lanes 13 and 16, 60 ng. The glycerol gradient purified ERCC2/CAK
fraction was added as follows: lane 8, 0.5 ng; lanes 5-7, 9, and 14-16,
1 ng; and lane 10, 2 ng.
TFIIH holoenzyme stimulated transcription (lanes 2-4); fur-
ther supplementation of the reaction with the ERCC2/CAK
complex did not increase the activity observed with TFIIH
alone (lanes 5-7). In the presence of low levels of TFIIH,
ERCC2/CAK reproducibly inhibited the reaction (compare
lanes 2 and 5). In the absence of TFIIH, ERCC2/CAK did not
support transcription (lanes 8-10). TFIIH* supported tran-
scription when added in place of TFIIH (lanes 11-13). When
ERCC2/CAK was added to the transcription mixture in the
presence of TFIIH*, transcription was markedly stimulated
(lanes 14-16). Quantitation of the full-length transcription
product indicated that at the low level of TFIIH*, stimulation
by ERCC2/CAK is nearly 25-fold (compare lanes 11 with 14).
This stimulation was reduced (2- to -3-fold) with higher levels
of TFIIH* (compare lanes 12 and 13 with lanes 15 and 16).
CAK alone did not stimulate the TFIIH*-dependent pol
II-transcription (data not shown).
To quantitate the amount of TFIIH and TFIIH* used in this
assay, the amount of p62 and ERCC3 (XPB) proteins were
compared by immunoblot analysis. The results indicated that
nd p62 proteins the amount of these proteins present in the reaction shown in
lot assay of the lane 3 (TFIIH) was approximately 100-fold lower than that in
h aERCC3 and lane 12 (TFIIH*) (data not shown), whereas similar levels of
iide gel (10%)/ transcription were observed in these two reactions. Thus, the
actions (10 1,u). relative specific activity of TFIIH* was much lower than that
he left and the of the TFIIH holoenzyme. The marked stimulation of TFIIH*
the right. (C) but not TFIIH-dependent transcription by ERCC2/CAK sug-
CAK/ERCC2 gests that inefficient transcription by TFIIH* may result fromycerol gradaent its deficiency of ERCC2 (XPD) (below the detectable levels).
iRCC2*fraction Effects of ERCC2/CAK and TFIIH* on Excision Repair.
6 jig of TFIIH The repair activity of ERCC2/CAK and TFIIH* was exam-
)rapkin and D. ined in the excision assay using a double-stranded 140 mer as
substrate. This DNA fragment contained a centrally located
cholesterol lesion and a 32P-label positioned in the sixth
ained<1% of phosphodiester bond, 5' to the lesion. The excision assay
La not shown). measures release of the excision products (27-29 nt in length)
II-Catalyzed that arise from dual incisions that occur at the fifth phos-
and ERCC2/ phodiester bond 3' and the 21st-23rd phosphodiester bond 5'
)ns containing to the lesion (25, 26). Extracts derived from Chinese hamster
rFIlE, TFIIF, ovary cell lines deficient in XPB (ERCC3) and XPD (ERCC2)
the absence of complementation groups were tested for excision repair in a
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TFIIH* and ERCC2/CAK fractions. As shown in Fig. 5,
whereas XPB CFEs were efficiently complemented by TFIIH*
(lane 9), excision with XPD extracts was poorly complemented
by this fraction (lane 10). ERCC2/CAK complemented XPD
extracts (lane 12) but not XPB (lane 11). No excision products
were detected in reactions containing XPB extracts with
ERCC2/CAK even after long exposures of autoradiograms
(data not shown). This is consistent with the finding that
ERCC2/CAK is devoid of XPB (ERCC3).
The low complementation efficiency of XPD (ERCC2)
extract with the ERCC2/CAK fraction used was due to the low
concentration ofERCC2 (XPD). It was observed that addition
of a more concentrated fraction of ERCC2/CAK resulted in
higher levels of XPD complementation, indicating that this
reaction is ERCC2 (XPD) concentration-dependent (data not
shown). A 32P-labeled band migrating slightly below the 27-
mer excision product was an experimental artifact.
DISCUSSION
We have developed purification procedures that lead to the
isolation of two human TFIIH-related complexes, TFIIH* and
ERCC2/CAK. A specific association between mammalian
ERCC2 (XPD) and CAK was first suggested by Roy et al. (7),
who studied the interactions between cdk7 and TFIIH subunits
present in TFIIH preparations by immunochemical means.
They observed that (i) antibodies against ERCC2 (XPD) and
cdk7 immunoprecipitated similar proportions of ERCC2
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FIG. 5. Complementation of CFEs with TFIIH* and ERCC2/
CAK in the excision repair reaction. Internally labeled cholesterol-
containing substrate was incubated with 50 ,ug CFE (25 ,ug each in the
complementation assay shown in lanes 6-8) and supplemented with
purified proteins where indicated (lanes 9 and 10, 15 ng TFIIH* or
lanes 11 and 12, 2 ng of ERCC2/CAK). For comparison, the excision
observed with HeLa and AA8 CFEs are shown in lanes 1 and 2; HeLa
cells are the source of purified proteins and AA8 is the wild-type
Chinese hamster ovary parental cell line for the mutant cell lines used
(XPB (UV24), XPD (UV5), and XPG (UV135)).
of cdk7 antibodies disassociated cdk7 and 30% of the ERCC2
(XPD) protein from the CAK containing-TFIIH complex; and
(iii) ERCC2 (XPD) and cdk7 coeluted from an ERCC2-
antibody affinity column to which a TFIIH fraction had been
applied. Our finding that ERCC2 (XPD) forms a complex with
CAK is consistent with these results and suggests a direct link
between a DNA helicase required for excision repair/
transcription and a cell cycle regulator.
CAK is a CTD kinase (7) whose role in transcription is not
fully understood. There has been no evidence indicating a
direct role ofCAK in excision repair. In light of findings in this
report, CAK may play an essential role for assembling ERCC2
(XPD) and "core" TFIIH (TFIIH*) into the TFIIH holoen-
zyme. CAK may play an indirect role such as its phosphory-
lation of the CTD and/or its association with TFIIH may
initiate signaling pathways that coordinate cell cycle, transcrip-
tion, and/or excision repair.
TFIIH* is a subsetofTFIIH containing ERCC3 (XPB), p62,
p44, p41, and p34 but lacking detectable levels of ERCC2
(XPD) and CAK. TFIIH* and ERCC2/CAK may be two
distinct subassemblies of TFIIH. The relative concentrations
of TFIIH, ERCC2/CAK, and TFIIH* in a cell have yet to be
determined. Different forms of TFIIH have been found in
yeast (29, 30). Yeast TFIIH active in transcription can be
dissociated into three components: (i) a 5-subunit core con-
taining RAD3 (ERCC2), TFB1 (p62) and SSL1 (p44); (ii) the
SSL2/RAD25 (ERCC3) gene product; and (iii) a complex of
p47, p45, and p33 that is associated with a CTD kinase activity.
There appears to be a difference in the interactions among the
TFIIH homologous subunits of yeast and human. Most no-
ticeably, human ERCC3 (XPB), but not ERCC2 (XPD),
interacts with p62, p44, p41, and p34 to form a five-subunit
"core" complex (TFIIH*). The association of ERCC3 (XPB)
with this complex is stable in high salt (0.3M NaCl) and
detergent (0.5% NP-40) (data not shown). In contrast, ERCC2
(XPD) can be readily separated from this "core" TFIIH
complex but interacts with CAK to form a complex.
Our finding that the TFIIH*-dependent pol II-transcription
can be markedly stimulated by ERCC2/CAK demonstrates
that ERCC2 (XPD) plays an active role in pol II-transcription.
In light of the observation of Guzder et al. (31) that the yeast
homologue of ERCC2 (RAD3) is required for transcription
and the finding of Bardwell et al. (32) that RAD3 interacts with
ERCC3 (RAD25) and SSL1 (p44), it is likely that ERCC2/
CAK and TFIIH* interact to assemble the TFIIH holoenzyme.
This notion was further substantiated by our repair-
complementation experiments with TFIIH* and ERCC2/
CAK; these two complexes complemented ERCC3 (XPB)-
and ERCC2 (XPD)-mutant cell extracts, respectively, to sup-
port excision repair. We propose that TFIIH* complements
ERCC3 (XPB)-repair deficient extracts by interacting with the
ERCC2 (XPD) protein (either complexed with CAK or as the
free subunit) in the mutant extracts to form the TFIIH
holoenzyme. Similarly, ERCC2/CAK complements ERCC2
(XPD)-deficient extracts by interacting with TFIIH* present in
the ERCC2 (XPD) mutant extracts.
Several questions to be addressed arise from the results of
this study. Does the assembly of TFIIH from TFIIH* and
ERCC2/CAK- have physiological significance? Could this
assembly impose a rate-limiting step for pol II-catalyzed
transcription and/or excision repair? Would TFIIH dissociate
into TFIIH* and ERCC2/CAK during transcription or exci-
sion repair reactions as a necessary step? Does the interaction
between TFIIH* and ERCC2/CAK influence the ATPase/
helicase activities of ERCC2 (XPD) and ERCC3 (XPB)?
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